Orthofix Medical (NASDAQ:OFIX) Earns Outperform Rating from Barrington Research
Barrington Research reissued an "Outperform" rating for Orthofix Medical (NASDAQ:OFIX) with an $18 price target, indicating a 34.5% potential upside. Despite this, the overall analyst consensus is a "Hold" with a target of $20. Insider transactions show recent selling by the CEO and CFO, while institutional investors hold a significant majority of the stock.
Orthofix Medical (OFIX) to Release Quarterly Earnings on Tuesday
Orthofix Medical (OFIX) is scheduled to release its Q4 2025 earnings before the market opens on Tuesday, February 24th, with analysts expecting adjusted earnings of $0.44 per share and revenue of $218.715 million. Recent insider sales include the CFO selling 4,873 shares and the CEO selling 9,797 shares in January, totaling $370,958 in insider sales over the last 90 days. The company currently holds a "Hold" consensus rating from analysts with an average price target of $20.00.
The Technical Signals Behind (OFIX) That Institutions Follow
This article provides a technical analysis of Orthofix Medical Inc. (OFIX), highlighting a near-term strong sentiment despite neutral mid and long-term outlooks. It details institutional trading strategies, including long, breakout, and short setups with specific entry zones, targets, and stop losses. The analysis is based on AI-generated signals and multi-timeframe signal analysis, aimed at helping institutions and traders optimize their positions.
Orthofix to Participate in Upcoming Investor Conferences
Orthofix Medical Inc. announced that its President and CEO, Massimo Calafiore, and CFO, Julie Andrews, will participate in two upcoming investor conferences in March 2026: the Canaccord Genuity Musculoskeletal Conference and the TD Cowen 46th Annual Health Care Conference. Interested parties can access live and archived webcasts of these presentations on the company's Investor Relations website. Orthofix, a global medical technology company, regularly shares important updates through its investor relations page.
Precision Trading with Orthofix Medical Inc. (OFIX) Risk Zones
This article provides an AI-driven analysis of Orthofix Medical Inc. (OFIX), highlighting neutral sentiment in the near term and potential mid-term weakness. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones, along with a multi-timeframe signal analysis. The report emphasizes risk management and offers institutional-grade tools to optimize trading decisions.
Orthofix Medical to Announce 2025 Financial Results on February 25, 2026 with Webcast Scheduled
Orthofix Medical Inc. announced it will release its financial results for the fourth quarter and full year of 2025 on February 25, 2026. The company will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day to discuss its financial performance, including revenue and operational updates. Orthofix, a medical device manufacturer focusing on orthopedic solutions, expects these disclosures to provide insights into its business operations.
Orthofix to Report Fourth Quarter and Full-Year 2025 Financial Results
Orthofix Medical Inc. announced it will release its fourth quarter and full-year 2025 financial results on Tuesday, February 24, 2026, before market open. The company will host a conference call and webcast on the same day at 8:30 am Eastern Time to review the results. Interested parties can access the call via a provided phone number or the webcast on Orthofix's investor relations website.
Orthofix Medical Inc. (NASDAQ:OFIX) Receives Average Rating of "Hold" from Analysts
Seven analysts have issued an average "Hold" rating for Orthofix Medical Inc. (NASDAQ:OFIX), with an average 12-month price target of $20.00. Recent insider selling by CFO Julie Andrews and CEO Massimo Calafiore has been reported, disposing of shares worth $370,958 over the last quarter. The company's stock opened at $13.45, with a market cap of $532.62 million, and a negative P/E ratio of -4.44.
Orthofix Medical Inc. (OFIX) Investor Outlook: Exploring a 64.86% Potential Upside in Medical Devices
Orthofix Medical Inc. (OFIX) is a medical technology company with a potential upside of 64.86% according to analyst ratings, despite current profitability challenges. The company, which specializes in spinal and orthopedic care, has strong revenue growth and free cash flow but is not currently profitable. Investors are advised to consider the promising growth potential against the financial health challenges.
Orthofix Medical (NASDAQ:OFIX) Now Covered by Analysts at TD Cowen
TD Cowen has initiated coverage on Orthofix Medical (NASDAQ:OFIX) with a "hold" rating and a $14 price target. This aligns with MarketBeat's consensus "hold" rating and a $20 average target. Insider selling has been observed recently, with CFO Julie Andrews and CEO Massimo Calafiore selling shares, resulting in insiders owning about 1.30% of the stock.
Orthofix Medical’s Stock Under Pressure: Can OFIX Turn Clinical Promise Into Shareholder Returns?
Orthofix Medical's stock has been under significant pressure, showing a downward trend despite the company's product innovation and post-merger integration efforts. While analysts have mixed ratings, leaning towards "Hold" or "Buy" with theoretical upside, they remain cautiously skeptical, awaiting clearer signs of revenue acceleration and margin expansion. The company's future performance hinges on procedure volume trends, successful merger integration, margin improvement, and the commercial success of its innovations in spinal implants, biologics, and bone growth stimulation devices.
Technical Reactions to OFIX Trends in Macro Strategies
This article from Stock Traders Daily analyzes Orthofix Medical Inc. (NASDAQ: OFIX) using AI models to suggest trading strategies. It highlights weak near and mid-term sentiment, a neutral long-term outlook, and recommends specific entry, target, and stop-loss zones for position, momentum breakout, and risk hedging strategies. The analysis points to an exceptional risk-reward short setup.
Andrews Julie, CFO of Orthofix, sells $70k in OFIX stock By Investing.com
Andrews Julie, CFO of Orthofix Medical Inc. (NASDAQ:OFIX), sold 4,873 shares of company stock worth $70,073 on January 16, 2026. This transaction was executed to cover tax withholding obligations related to restricted stock units and was mandated by the company's Compensation and Talent Development Committee. Orthofix recently reported mixed Q3 2025 financial results, with an earnings per share miss but exceeding revenue expectations.
Andrews Julie, CFO of Orthofix, sells $70k in OFIX stock
Orthofix Medical Inc.'s CFO, Julie Andrews, sold 4,873 shares of OFIX stock worth over $70,000 to cover tax withholding obligations tied to restricted stock units. This transaction was mandated by the company's Compensation and Talent Development Committee. Separately, Orthofix recently reported mixed Q3 2025 financial results, with an earnings per share miss but a revenue beat.
Andrews Julie, CFO of Orthofix, sells $70k in OFIX stock
Orthofix Medical Inc.'s CFO, Julie Andrews, sold 4,873 shares of OFIX stock for $70,073 on January 16, 2026. This transaction was executed to cover tax withholding obligations related to restricted stock units and was mandated by the company's Compensation and Talent Development Committee. The company previously reported mixed Q3 2025 financial results with an EPS miss but a revenue beat.
Andrews Julie, CFO of Orthofix, sells $70k in OFIX stock By Investing.com
Julie Andrews, CFO of Orthofix Medical Inc. (NASDAQ:OFIX), sold 4,873 shares of common stock for $70,073 to cover tax withholding obligations related to restricted stock units. This sale, mandated by the board, leaves her with 58,039 shares. Separately, Orthofix reported a Q3 2025 earnings miss but exceeded revenue expectations.
Orthofix Medical (NASDAQ:OFIX) CFO Julie Andrews Sells 4,873 Shares of Stock
Orthofix Medical's CFO, Julie Andrews, sold 4,873 shares of OFIX stock on January 16th for approximately $70,074, reducing her stake by 7.75%. Despite this insider selling, the stock traded up 1.5% to $13.85, and institutional investors have significantly increased their holdings in the company. Analysts currently rate the stock as a "Moderate Buy" with an average target price of $21.50.
Bone Growth Stimulator Market Covering Prime Factors
The Bone Growth Stimulator Market is expanding due to an increase in orthopedic surgeries, higher fracture incidences, and a growing geriatric population. Technological advancements in wearable devices and ultrasound are enhancing treatment effectiveness. Key companies include Medtronic Plc, Orthofix Medical Inc., and Stryker Corporation, with the market expected to focus on outpatient usage, home-based therapy, and post-surgical rehabilitation by 2026.
Further weakness as Orthofix Medical (NASDAQ:OFIX) drops 9.0% this week, taking five-year losses to 68%
Orthofix Medical Inc. (NASDAQ: OFIX) share price has dropped 68% over the last five years, including a 9.0% decline this past week and 20% over the last year. Despite a 17% per year revenue growth over the last half-decade, the stock has underperformed, suggesting investor focus may be shifting to profitability. Analysts are examining the company's path to profitability, especially given insider share purchases, indicating some confidence in its future.
This Insider Has Just Sold Shares In Orthofix Medical
Orthofix Medical Inc. (NASDAQ: OFIX) President Massimo Calafiore recently sold US$301k worth of stock at US$15.52 per share, reducing his holding by 19%. While this is the largest insider sale in the past year, it occurred around the current share price of US$14.40, lessening immediate concern. Overall, insider selling has outpaced buying over the last year, and ownership by insiders remains relatively low at 1.2%, suggesting caution for potential investors.
This Insider Has Just Sold Shares In Orthofix Medical
Orthofix Medical Inc. (NASDAQ:OFIX) recently saw its President, Massimo Calafiore, sell US$301k worth of stock, reducing his holding by 19%. While this was the largest insider sale in the last year, it occurred around the current market price, making it less concerning than a sale at a significantly lower price. Despite some insider buying within the last year, overall insider selling outweighed buying, and insiders hold a relatively small 1.2% ownership in the company.
Further weakness as Orthofix Medical (NASDAQ:OFIX) drops 9.0% this week, taking five-year losses to 68%
Orthofix Medical (NASDAQ:OFIX) has experienced significant weakness, with its stock dropping 9.0% this week and accumulating a 68% loss over the past five years. Despite this, the company has seen consistent revenue growth of 17% per year over the last half-decade, which is strong for a pre-profit company. Insiders have also been buying shares, suggesting potential confidence in future performance, though profitability remains a key concern for investors.
Orthofix Medical CEO Calafiore sells $300k in stock By Investing.com
Massimo Calafiore, President and CEO of Orthofix Medical (NASDAQ:OFIX), sold 19,397 shares of company stock across two days in January, totaling approximately $300,955. This transaction leaves him with 217,237 shares directly owned. The sales occurred shortly after the company reported a mixed financial performance for Q3 2025, missing EPS forecasts but exceeding revenue expectations.
Orthofix Medical CEO Calafiore sells $300k in stock
Orthofix Medical President and CEO Massimo Calafiore sold 19,397 shares of company stock for over $300,000 in January. These sales followed the company's Q3 2025 earnings report, which showed a significant EPS miss but exceeded revenue expectations.
Orthofix Medical (NASDAQ:OFIX) CEO Massimo Calafiore Sells 9,600 Shares
Orthofix Medical (NASDAQ:OFIX) CEO Massimo Calafiore sold 9,600 shares of company stock on January 9th for $15.82 per share, totaling $151,872. This transaction, along with a previous sale of 9,797 shares on January 12th, reduced his ownership by 4.06% to 227,034 shares. Analysts currently rate OFIX as a "Moderate Buy" with a consensus target price of $21.50, despite its recent trading performance and various insider and institutional trading activities.
Massimo Calafiore Sells 9,797 Shares of Orthofix Medical (NASDAQ:OFIX) Stock
Massimo Calafiore, CEO of Orthofix Medical (NASDAQ:OFIX), sold 9,797 shares of the company's stock on January 12th for approximately $149,012, reducing his stake by 4.32%. The stock was trading down 2.9% at $14.81, with a market capitalization of $586.5 million. Institutional investors own nearly 90% of OFIX, and analysts have a "Moderate Buy" consensus rating with a target price of $21.50.
Orthofix - Model M6-C - Artificial Cervical Disc
The Orthofix M6-C artificial cervical disc is designed to mimic the natural movement and structure of a vertebral disc to preserve motion for patients undergoing cervical disc replacement. It features an artificial nucleus and woven fiber annulus, aiming to provide an innovative non-fusion solution for degenerative cervical disc conditions. The product is indicated for single-level discectomy patients with intractable degenerative cervical radiculopathy after failed conservative treatments.
The Truth About Orthofix Medical Inc (OFIX): Underdog Stock or Total Flop?
This article examines Orthofix Medical Inc (OFIX), a medical technology company specializing in spine and orthopedic solutions, to determine if it is an undervalued underdog or a risky investment. It highlights the company's focus on essential medical devices, its position as a "turnaround med-tech" with execution risk, and its competition with larger industry players. The piece concludes that OFIX is a high-risk, potentially high-reward speculative bet on a turnaround story, suitable for investors willing to conduct thorough research rather than chasing hype.
The Truth About Orthofix Medical Inc (OFIX): Underdog Stock or Total Flop?
This article analyzes Orthofix Medical Inc (OFIX), a low-key spine and orthopedics company, to determine its potential as an underdog stock. It examines the company's business model, risk profile, and competitive landscape, concluding it's a high-risk, potentially underpriced med-tech underdog that requires strong execution to justify investment. The piece suggests OFIX could be a contrarian play for investors willing to undertake research and tolerate volatility.
Squarepoint Ops LLC Purchases 98,552 Shares of Orthofix Medical Inc. $OFIX
Squarepoint Ops LLC significantly increased its stake in Orthofix Medical Inc. (NASDAQ:OFIX) by 515.6% during the second quarter, acquiring an additional 98,552 shares to bring its total ownership to 117,666 shares. This investment is valued at $1.312 million, representing approximately 0.30% of the company. Other institutional investors have also adjusted their holdings in Orthofix, which maintains a "Moderate Buy" consensus rating from analysts with a target price of $21.50.
Orthofix Medical Inc. (NASDAQ:OFIX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Orthofix Medical Inc. (NASDAQ:OFIX) has received a "Moderate Buy" consensus rating from six brokerage firms, with an average 12-month price target of $21.50. The stock, which opened at $15.49, trades below this target, suggesting potential upside. Institutional ownership is high at nearly 90%, with several major hedge funds increasing their stakes in recent quarters.
Fracture Fixation Products Market Insights 2025-2032: Led by North America 38.8% Market Share | Wright Medical Group N.V, Orthofix Medical Inc., Integra LifeSciences, Arthrex Inc
The global Fracture Fixation Products Market reached US$ 9.1 billion in 2023 and is projected to grow to US$ 16.34 billion by 2031, with a CAGR of 7.8% during the forecast period 2024-2031. North America leads the market with a 38.8% share, driven by demand for advanced locking plates, bioresorbable systems, and minimally invasive techniques. Key players like Stryker, Zimmer Biomet, and Synthes are focusing on innovation in dynamic compression implants and small-fragment systems.
AYAL Capital Advisors Ltd Increases Holdings in Orthofix Medical Inc. $OFIX
AYAL Capital Advisors Ltd significantly increased its stake in Orthofix Medical Inc. (NASDAQ:OFIX) by 74.7% in the second quarter, making it their second-largest holding. Other institutional investors also boosted their positions in Orthofix Medical. The company currently has a "Moderate Buy" rating from analysts with an average target price of $21.50.
Orthofix Medical Inc. $OFIX is Engine Capital Management LP's 3rd Largest Position
Engine Capital Management LP significantly increased its stake in Orthofix Medical Inc. (NASDAQ:OFIX), making it their third-largest holding. Despite mixed analyst sentiment, with a "Moderate Buy" consensus, Orthofix shares opened at $15.71 with a market capitalization of $622 million, and institutional investors now own 89.76% of the company.
Gabelli Funds LLC Raises Stake in Orthofix Medical Inc. $OFIX
Gabelli Funds LLC significantly increased its stake in Orthofix Medical Inc. (NASDAQ:OFIX) by 70.8% in Q2, bringing their total holdings to 257,123 shares valued at approximately $2.87 million. This move is part of a broader trend with several other institutional investors also increasing or initiating positions in OFIX, resulting in institutional investors and hedge funds owning nearly 90% of the company's stock. Analysts currently rate Orthofix Medical as a "Moderate Buy" with an average price target of $21.50.
Trauma Fixation Devices Market size to exceed $18.9 Billion
The Trauma Fixation Devices Market is predicted to grow from $8.9 billion in 2025 to $18.9 billion by 2035, exhibiting a CAGR of 7.8%. This growth is driven by increasing procedural volumes, technological advancements in orthopedics, and improved access to trauma care globally. North America is expected to remain the dominant market, while the Asia Pacific region is projected to be the fastest-evolving due to healthcare infrastructure improvements and a rising geriatric population.
How (OFIX) Movements Inform Risk Allocation Models
This article analyzes Orthofix Medical Inc. (NASDAQ: OFIX) using AI models, revealing mixed sentiment across horizons and testing resistance. It outlines three distinct trading strategies: a Long Position Trading Strategy with a target of $16.02, a Momentum Breakout Strategy, and a Risk Hedging Strategy with a short entry zone. The analysis also provides multi-timeframe signal analysis, showing varying signal strengths and support/resistance levels.
Geode Capital Management LLC Buys 64,788 Shares of Orthofix Medical Inc. $OFIX
Geode Capital Management LLC increased its stake in Orthofix Medical Inc. (NASDAQ:OFIX) by 7.5% during the second quarter, acquiring an additional 64,788 shares to bring its total holdings to 930,252 shares, valued at approximately $10.37 million. This move is part of broader institutional investor activity in OFIX, with several other hedge funds also adjusting their positions. Despite mixed analyst sentiment, the stock holds an average "Moderate Buy" rating with an average target price of $21.50.
Orthofix at UBS Global Healthcare Conference: Strategic Innovations Unveiled
Orthofix Medical Inc. (NASDAQ:OFIX) presented its strategic vision at the UBS Global Healthcare Conference 2025, outlining a robust financial recovery and growth strategy focused on innovation and market expansion. The company aims for significant net sales CAGR and adjusted EBITDA by 2027, driven by new product launches like Virata and TruLock Elevate, and strategic advancements in its 7D Flash Navigation system. Orthofix emphasized its strong position in the spine and bone growth therapy markets, capitalizing on industry consolidation and optimizing its distribution network for profitable growth.
Here's What Analysts Are Forecasting For Orthofix Medical Inc. (NASDAQ:OFIX) After Its Third-Quarter Results
Orthofix Medical Inc. recently released its third-quarter results, showing a 5.1% share price drop despite revenues beating expectations by 2.8%. Analysts anticipate revenues of US$857.0m in 2026 and a significantly reduced loss per share, narrowing to US$1.68, though previous forecasts had a slightly lower loss expectation. Despite some mixed consensus on per-share loss expectations, the average price target remains unchanged, suggesting the company is performing in line with overall expectations.
Orthofix Medical Inc. (NASDAQ:OFIX) Q3 2025 Earnings Call Transcript
Orthofix Medical Inc. (NASDAQ:OFIX) reported strong Q3 2025 results, with solid year-over-year and sequential revenue growth driven by U.S. Spine and Orthopedics. The company achieved its seventh consecutive quarter of adjusted EBITDA margin expansion and positive free cash flow generation, reflecting disciplined operational efficiency. Orthofix also narrowed its full-year 2025 guidance and highlighted the successful adoption of its 7D FLASH navigation system and upcoming launch of the VIRATA Spinal Fixation system.
Orthofix Reports Third Quarter 2025 Financial Results
Orthofix Medical Inc. reported solid financial results for Q3 2025, with net sales of $205.6 million and pro forma net sales of $203.4 million, showing significant growth compared to Q3 2024. The company achieved its seventh consecutive quarter of adjusted EBITDA margin expansion and positive free cash flow. Orthofix narrowed its full-year 2025 net sales guidance and raised the low end of its adjusted EBITDA guidance, reflecting strong commercial momentum across its spine and orthopedics businesses.
Orthofix Medical Inc (NASDAQ:OFIX) Surpasses Q3 2025 Profit Expectations Despite Muted Market Reaction
Orthofix Medical Inc (NASDAQ:OFIX) significantly surpassed Q3 2025 profit expectations, reporting a non-GAAP EPS of $0.20 against an estimated loss of $(0.41), and net sales of $205.6 million exceeding consensus. Despite strong financial performance and increased adjusted EBITDA, the stock saw a muted market reaction, trading down 4.3% pre-market. The company also updated its full-year 2025 guidance, narrowing sales expectations but raising the lower end of its adjusted EBITDA forecast.
Orthofix Medical Inc (OFIX) Q3 2025 Earnings Call Highlights: Strong Growth in US Spine and ...
Orthofix Medical Inc. (OFIX) reported strong Q3 2025 results with significant revenue growth in US spine and orthopedics, marking its seventh consecutive quarter of adjusted EBITDA margin expansion. The company's success is attributed to its go-to-market strategy, distributor transitions, and innovative products like the 7D flash navigation system and Virada system, despite facing challenges such as price decreases at a major account and potential Q4 growth deceleration. Orthofix highlighted its strategic path towards achieving a 6.5% to 7.5% CAGR by 2027, with growth weighted towards that year due to key product launches.
Orthofix and MTF Biologics Expand Partnership Agreement
Orthofix and MTF Biologics have renewed and expanded their partnership, extending Orthofix’s exclusive marketing rights to the Trinity allograft line through 2032. The agreement also includes the development of a new demineralized bone matrix (DBM) to be marketed under Orthofix’s Legacy brand, enhancing their biologic portfolio for spine and orthopedic surgical applications. This collaboration aims to provide innovative solutions and value to customers and patients, with the Legacy DBM expected to be available in Q3 2022.
Orthofix Medical Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Orthofix Medical, Inc. has formed a Golden Cross, a technical indicator suggesting a potential bullish trend. The stock has recently outperformed the S&P 500 in daily and weekly performance, despite a year-to-date decline. While recent activity is promising, the company still faces broader market challenges, and investors will monitor if this Golden Cross leads to sustained upward momentum.
Orthofix to Participate in Upcoming Investor Conferences - Business Wire
Orthofix Medical Inc. (NASDAQ:OFIX) announced its participation in several upcoming investor conferences. Massimo Calafiore, President and CEO, and Julie Andrews, CFO, will present at the UBS Global Healthcare Conference, Stifel Healthcare Conference, and Jefferies Global Healthcare Conference. Live and archived webcasts of the presentations will be available on the Orthofix Investor Relations Website.
Barrington Lifts PT on Orthofix Medical (OFIX) to $17 From $16, Keeps an Overweight Rating
Barrington analyst Michael Petusky raised the price target for Orthofix Medical Inc. (OFIX) to $17 from $16, maintaining an Outperform rating. This decision follows Orthofix's strong fiscal Q2 2025 results, which reported net sales of $203.1 million and a 4% pro forma constant currency growth compared to Q2 2024. The company affirmed its 2025 outlook, driven by solid performance in its U.S. Spine Fixation and Bone Growth Therapies segments.
Orthofix stock rises on Street-beating Q2
Orthofix (NASDAQ: OFIX) saw its stock rise by nearly 15% after reporting strong second-quarter results that surpassed Wall Street expectations. The company posted a loss of $14.1 million on sales of $203.1 million, with adjusted earnings per share of 13¢, beating forecasts by 9¢. Orthofix also reaffirmed its sales guidance for the full year, indicating confidence in its three-year transformation plan and future growth through new product launches.
Earnings call transcript: Orthofix beats Q2 2025 forecasts, stock surges
Orthofix (OFIX) exceeded Q2 2025 forecasts with an EPS of -0.36 and revenue of $203.12 million, leading to a 15.21% stock surge in pre-market trading. The company reported strong growth in US Orthopedics and Bone Growth Therapies, driven by new product launches and FDA clearances, and projects full-year net sales between $800 million and $816 million. Management emphasized strategic priorities including commercial execution, gross margin improvement, and disciplined capital allocation to achieve profitable growth.
